Qeverisin

Qeverisin is a cyclic decapeptide antibiotic described in the context of speculative microbiology as a lead compound derived from the soil-dwelling bacterium Qevera sp. It is identified in studies of nonribosomal peptide natural products as a potential candidate for development of next-generation antimicrobials.

The molecule consists of ten amino acid residues linked in a head-to-tail cyclic backbone and includes two non-proteinogenic amino acids. This composition provides conformational rigidity and proteolytic stability. The nominal molecular weight is about 1,100 Da. Qeverisin is broadly amphipathic, with hydrophobic side chains forming a nonpolar interior and polar groups exposed to the solvent, a arrangement that influences both ribosomal interaction and membrane association.

Biosynthesis occurs via a nonribosomal peptide synthetase (NRPS) gene cluster, designated QEV-A through QEV-F. The cluster encodes modules that sequentially assemble the decapeptide and cyclize it to the final ring. Expression is regulated by environmental cues, including nutrient limitation and soil-derived signals, reflecting its natural role as a competitive metabolite in microbial communities.

Mechanism of action studies suggest Qeverisin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at a site distinct from classical macrolide targets, leading to impaired translocation. The compound has shown activity primarily against Gram-positive pathogens in early in vitro assays, with limited activity on many Gram-negative bacteria due to permeability barriers.

Discovery and naming trace to a 2028 program at the Institute for Synthetic Microbiology, which screened soil-derived NRPS products. The name combines the source region, Qevera, with the suffix common to peptide antibiotics. As of now, qeverisin remains in the preclinical stage, with ongoing work on pharmacokinetics, toxicity, and derivative optimization.